報價延遲最少15分鐘:2025/05/12 11:06 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.387999 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.50/--
|
|
企業價值
2.55M
|
| 資產負債 |
|
每股賬面淨值
0.13
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/12 11:06 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target. |